Eva Jack

Chief Business Officer, Mersana Therapeutics

Eva Jack

Ms. Jack joined Mersana in 2013 after serving as advisor to biotech companies and investors on business and financing strategies. She brings a history of venture capital and business development expertise to Mersana. Previously, from 2010 to 2012, she served as the Chief Business Officer of Pulmatrix, and before that, she was with MedImmune, the worldwide biologics unit of AstraZeneca. Most recently, Ms. Jack was Managing Director of MedImmune Ventures, where she was responsible for making and managing investments in private biotechnology companies. Prior to MedImmune Ventures, she was in MedImmune’s Business Development group, and in this role, she was responsible for in-licensing, out-licensing and research collaborations with universities, medical research institutions, governments and companies. Her responsibilities included identifying new and interesting research that these organizations are conducting in the therapeutic areas of cancer, infectious diseases and autoimmune diseases. Prior to joining MedImmune in 2004, Ms. Jack held a variety of positions at Intel Corporation, where she worked in venture investments, corporate strategy and public policy. Ms. Jack holds a bachelor’s degree from the University of Virginia and a master’s degree in health sciences from The Johns Hopkins University.